Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on
Go back to Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on| (NASDAQ: ROIV) | Delayed: 38.99 -0.78 (1.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.77 | 52 Week High | $ | |||
| Open | $39.02 | 52 Week Low | $ | |||
| Day High | $39.90 | P/E | N/A | |||
| Day Low | $38.72 | EPS | $ | |||
| Volume | 5,620,753 | |||||
